Domainex announces the appointment of Dr. Eddy Littler as non-executive Chairman

Written by: Nola Cadman
Published On: 8 Jun 2020

Following the retirement of Tony Brampton, Eddy Littler has been appointed as non-executive Chairman of Domainex Ltd

Eddy began his research career at the University of Leeds obtaining his PhD in virology.  After postdoctoral research at McMaster University in Canada, he joined the Paterson Institute for Cancer Research in Manchester. Eddy held senior positions with Wellcome Research Laboratories, GSK and Medivir, where he led the team that discovered Olysio which was a major drug for treatment of hepatitis C virus. Eddy became CEO of Domainex in May 2008 and developed Domainex to become one of the UK’s leading drug discovery CROs. In October 2016, Eddy joined ReViral as CEO. ReViral is a UK-based biotechnology company developing therapies for respiratory syncytial virus by developing novel first-in-class medicines and in 2018 Eddy led the fundraising of $55million Series B investment for the Company.  He became COO in June 2019 as the Company moved into Phase 2 development. Eddy is also Chairman of Neuro-Bio based in Oxford, researching treatments for Alzheimer’s disease.

Domainex’s retiring chairman Tony Brampton commented: “I am delighted that Eddy Littler has agreed to return to Domainex as Chairman. I joined the Domainex board as a non-executive director in 2012 and had the privilege of working with Eddy for a number of years.  His deep understanding of Domainex’s business and extensive drug discovery expertise will be invaluable to the management team led by our CEO, Tom Mander, as we pursue an accelerated growth strategy and maintain our position at the forefront of drug discovery technology providers”.

Eddy Littler said: “I am pleased to have returned to Domainex. During my time as CEO I came to understand how much diverse drug discovery is driven by contract research organisations and how it is possible to establish a reputation for high-quality research within the sector. Since my departure, Domainex has moved from strength to strength growing in size and also in its establishment of advanced biological technologies for screening and developing compounds into drugs. I am eagerly anticipating taking over the position of Chairman and working with the Domainex team to help continue the successful years it has had under Tony Brampton’s guidance.